section name header

Pronunciation

a-kli-DIN-ee-um/for-MOH-te-rol

Classifications

Therapeutic Classification: bronchodilators

Pharmacologic Classification: anticholinergics, adrenergics

Indications

REMS


Action

  • Aclidinium: Acts as an anticholinergic by inhibiting the M3 receptor in bronchial smooth muscle. Formoterol: Beta2-adrenergic agonist that stimulates adenyl cyclase, resulting in accumulation of cyclic adenosine monophosphate and subsequent bronchodilation.
Therapeutic effects:
  • Improved airflow and exacerbations in COPD.

Pharmacokinetics

Absorption: Aclidinium: 6% systemically absorbed following inhalation; Formoterol: majority of inhaled drug is swallowed and absorbed.

Distribution: Unknown

Metabolism/Excretion: Aclidinium: Rapidly hydrolyzed; metabolites are not pharmacologically active. Metabolites are eliminated in urine (54–65%) and feces (20–33%); <1% excreted unchanged in urine. Formoterol: Mostly metabolized by the liver; 10–18% excreted unchanged in urine.

Half-Life: Aclidinium: 12 hr. Formoterol: 10 hr.

Time/Action Profile

(bronchodilation)

ROUTEONSETPEAKDURATION
Inhalation1 hr2–4 hr12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: angina, arrhythmias, hypertension, hypotension, palpitations, tachycardia

EENT: worsening of narrow-angle glaucoma

F and E: hypokalemia

GI: dry mouth, nausea

GU: urinary retention

Metab: hyperglycemia

MS: arthralgia, muscle cramps

Neuro: dizziness, headache, insomnia, nervousness, tremor

Resp: cough, PARADOXICAL BRONCHOSPASM

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Duaklir Pressair

Canadian Brand Names

Duaklir Genuair